14 drug(s) with this reaction
3,108 total reports
Inappropriate Schedule Of Product Administration has been reported as an adverse reaction across 14 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,108 adverse event reports mention inappropriate schedule of product administration in connection with Haleon Us Holdings Llc products.
This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with inappropriate schedule of product administration, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Haleon Us Holdings Llc drugs have inappropriate schedule of product administration listed in their FDA adverse event reports, sorted by report count:
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:
14 drug(s) manufactured by Haleon Us Holdings Llc have inappropriate schedule of product administration listed in their FDA adverse event reports: FLUTICASONE PROPIONATE, DOCOSANOL, IBUPROFEN SODIUM, IBUPROFEN TABLETS, COATED, GLYCERIN, LIDOCAINE, and others.
There are a combined 3,108 reports of inappropriate schedule of product administration across 14 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.